Navigation Links
American Capital Receives $60 Million From The Sale Of Lifoam Holdings And Generates An 11% Return On Its Investment
Date:1/17/2013

BETHESDA, Md., Jan. 17, 2013 /PRNewswire/ -- American Capital, Ltd. (Nasdaq: ACAS) ("American Capital") announced today that its portfolio company Lifoam Holdings, Inc. ("Lifoam") was sold to Jarden Corporation ("Jarden") (NYSE: JAH) on December 31, 2012.  American Capital received $60 million in debt and equity proceeds and realized a gain of $14 million, subject to post-closing adjustments.  American Capital's compounded annual rate of return earned on its debt and equity securities over the life of its investment was 11%, including interest, dividends, capital gain and fees.  

"American Capital's investment in Lifoam produced an attractive return for our shareholders," said Brian Graff , American Capital Senior Vice President and Senior Managing Director.  "We continue to search for new investment opportunities in a variety of business sectors, either as the sole investor in a One Stop Buyout® or with a sponsor in support of a private equity buyout."

Lifoam is a manufacturer and distributor of expandable polystyrene ("EPS") and polyurethane ("PUR") products for consumer, healthcare and commercial applications.  Lifoam's products include foam picnic coolers, reusable ice and freeze packs and sophisticated protective and thermal packaging products. 

"As a leader in each of its consumer, healthcare and commercial products business segments, Lifoam has demonstrated consistent and strong earnings growth even throughout the recession," said Jim Gregory , American Capital Principal, Buyouts Group.  "American Capital has been fortunate to partner with an exceptional management team, which has driven Lifoam's growth and successful expansion into the highly attractive healthcare cold chain packaging market.  We believe that Lifoam is a great addition to Jarden's business and will benefit from being part of the Jarden family."

Since American Capital's 1997 IPO through the third quarter of 2012, the company has earned a 10% compounded annual return, including interest, dividends, fees and net gains, on over 340 realizations of senior debt, subordinated debt, equity and structured products investments, totaling $18 billion of committed capital.  American Capital earned a 27% compounded annual return on the exit of its equity investments, including dividends, fees and net gains.

For a chart showing a partial listing of American Capital's exited portfolio companies, please go to http://www.americancapital.com/Pages/our_portfolio/exited.aspx .  

ABOUT AMERICAN CAPITAL
American Capital is a publicly traded private equity firm and global asset manager.  American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products.  American Capital manages $18.6 billion of assets, including assets on its balance sheet and fee earning assets under management by affiliated managers, with $118 billion of total assets under management (including levered assets).  From its eight offices in the U.S. and Europe, American Capital and its affiliate, European Capital, will consider investment opportunities from $10 million to $750 million.  For further information, please refer to www.AmericanCapital.com.

This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions, or changes in the conditions of the industries in which American Capital has made investments.

Contact:
Brian Graff , Senior Vice President and Senior Managing Director
Dustin Smith , Managing Director, Buyouts Group
Jim Gregory , Principal, Buyouts Group
212-213-2009


'/>"/>
SOURCE American Capital, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Earnings Forecast Stock Alerts: American International Group, Teva Pharmaceutical, CSX, Exxon Mobil, Lowes, and Seagate
2. Americans United for Life Celebrates Win for Illinois Conscience Rights in Case AUL Championed Since 2005
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. American Pacific to Release Financial Results and Hold Fiscal 2012 Year-End and Fourth Quarter Investor Teleconference
6. The American Council for Patient Liberty on medical marijuana vending machines
7. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
8. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
9. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
10. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
11. American Academy of Pain Medicine Safe Opioid Prescribing Course Proves Highly Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):